Objective-To evaluate the role of platelet activating factor (PAF) in the early stage of arthritis. Methods-Arthritis was induced in rabbits by weekly intra-articular injections of carrageenan. A PAF receptor antagonist, BN 50730, was used as a preventive or curative agent. Results-BN 50730 was able partially to prevent the development of arthritis, and was also active on established arthritis. The joint arthritis scores of BN treated animals were significantly lower than those of the non-treated animals. The blood concentrations of PAF, PAF bound to lipoproteins (lipo-PAF), and its precursor, lyso-PAF, were not correlated with clinical variations. Conclusions-The present data demonstrate a therapeutic action of a PAF antagonist in experimental arthritis and suggest a critical role for PAF during the early stage of arthritis.
Platelet activating factor (PAF) is a phospholipid mediator released by numerous inflammatory cells.' It is a potent activator of neutrophils and monocytes. In human pathology, the effects of PAF have been studied mainly on pulmonary and cardiovascular systems,' but its involvement in the amplification cycle of inflammatory reactions and its relationship with cytokines suggest it may be implicated in the physiopathology of arthritis. We recently reported the presence of PAF in blood and synovial fluid from patients with arthropathies, with increased concentrations in active rheumatoid arthritis.7 A PAF-degrading enzyme, acetylhydrolase, was also detected in RA in serum and synovial fluid.8
The present study was undertaken to evaluate the effects of blocking PAF in an experimental rabbit model of arthritis. Carrageenan, a mucopolysaccharide agent with proinflammatory properties, was used as the arthritogenic compound. The in the left knee of 10 mg carrageenan lambda 1% (Sigma) diluted in 1 ml saline. The right knee received no injection and served as a control. The PAF antagonist BN 50730 was administered intraperitoneally (ip) (5 mg/kg/day).
Five groups of five animals were studiedgroup 1: intra-articular (ia) carrageenan without treatments; group 2: ia carrageenan-BN 50730 ip from day 0 to day 60; group 3: ia carrageenan-ip injections of BN solvent from day 0 to day 60; group 4: ia carrageenanip BN treatment from day 28 to day 60; group 5: ia saline serum 1 ml-ip BN treatment from day 0 to day 60.
EVALUATION OF ARTHRITIS
Evaluation was performed at day 0, before each ia injection at days 7, 14, 21, 28, and at days 35, 45, and 60. Arthritis was evaluated blindly by measuring the joint diameter at the femoro-tibial level, and by an arthritis score: 0 = normal joint; 1 = mild arthritis; 2 = moderate arthritis; 3 = severe arthritis. The scoring system was defined according to the importance of the tumefaction (synovitis, synovial fluid, or both) and local heat. Venous blood was collected for measurement of PAF and derivatives.
At day 60, all rabbits were sacrified (intravenous pentobarbitone), and both knees were dissected. Histological analysis was performed blind by two observers. DETECTION A first set of analyses was performed for the period 0-60 days. Two other analyses were performed with the same tests on clinical parameters: one on the period 0-21 days and the second for the period 28-60 days.
Results

DEVELOPMENT OF ARTHRITIS
The animals from group 5, which received saline injections, did not develop arthritis during the study period.
Repeated ia injections of carrageenan induced arthritis in all rabbits, detectable at the end of the first week (fig 1) . At day 7, the left knee arthritis score was greater for animals not treated with BN (groups 1, 3, and 4) (analysis of variance and multiple range test, p < 0 05). In these groups, the maximal arthritis score was observed between two and three weeks. During the first four weeks, the non-treated rabbits exhibited a similar arthritis course. The BN solvent did not seem to have any particular effect, as rabbits from group 3 had arthritis scores quite similar to those of rabbits from group 1. For the non-treated animals (groups 1 and 3), the arthritis retained approximately the same intensity until the completion of the study.
During the first period (day 1 to day 28), BN treated rabbits (group 2) had lower arthritis scores than the non-treated animals (groups 1, 3, and 4) (analysis of variance, p < 0 05).
At day 28, the arthritis score was statistically identical in the three groups of animals which had not been previously treated with the PAF antagonist. However, when group 4 animals were then treated with PAF antagonist, the arthritis intensity score decreased dramatically to become identical to that of rabbits receiving the drug since day 0. A significant statistical difference (analysis of variance, p < 0 05) was observed between the five groups for the arthritis score during the first period of analysis. The multiple range test identified three homogeneous groups: groups 1, 3, and 4 were statistically similar; group 2 exhibited a milder arthritis; group 5 (without arthritis) was different from the two other groups.
During the second period of analysis (28-60 days), a statistical difference was still present between groups, but the group distribution changed: groups 1 and 3 were identical, group 4 became similar to group 2, and both were still different from group 5. The same statistical outcome was obtained from the two indices of arthritis-left joint diameter or joint diameter difference between left and right knee (fig 2) : there was a high correlation between arthritis score and left joint diameter (r = 0 90). The right knee (control, not injected) remained normal in all rabbits during the period of observation.
BIOLOGICAL PARAMETERS
An increase in circulating PAF was observed at day 7 in all groups. The greatest value was detected in group 2, without significant differences between groups. After the first two weeks, PAF was undetectable in most animals ( fig 3) . No correlation could be established between clinical and biological variables. All right knees were normal. A present in the left knee of all those from group 5, and twc group 4. The histological as that of a subacute synovitis, plasmocyte infiltration and j There was no difference in the , animals from group 2 comparec and 3.
reversed the clinical arthritis scores, which became identical to those of rabbits treated prophylactically. The therapeutic effect was derived from the drug itself, as the BN solvent had no action.
The blood concentrations of PAF were not correlated with the variations in clinical presentation. The increase in PAF concentration at day 7 could be explained partly by the action of the PAF antagonist, competing with naturally occurring PAF for its binding sites; inhibition of PAF binding to its receptors can also block its cellular metabolism. ' 
